Alnylam Pharmaceuticals Has Submitted An FDA Supplemental New Drug Application For Vutrisiran, For ATTR Amyloidosis With Cardiomyopathy
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for Vutrisiran, targeting ATTR amyloidosis with cardiomyopathy. This submission could potentially expand the use of Vutrisiran, impacting Alnylam's market position.
October 09, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for Vutrisiran, which could expand its use for treating ATTR amyloidosis with cardiomyopathy. This move may enhance Alnylam's market position and revenue potential.
The submission of a supplemental New Drug Application to the FDA is a significant step for Alnylam Pharmaceuticals. If approved, it could expand the use of Vutrisiran, potentially increasing the company's market share and revenue. This news is likely to positively impact ALNY's stock price in the short term as investors anticipate potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100